Impact of delay in interval debulking surgery after neoadjuvant chemotherapy on survival in ovarian cancer
Journal of the Pakistan Medical Association · 2025
DOI: 10.47391/jpma.20168 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Pakistan Medical Association, 2025. Verfasst von Kheyal Azam Khalil und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynaecologic Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Cytoreduction Surgical Procedures, Neoadjuvant Therapy, Time-to-Treatment. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objective
To determine the impact of delay between neoadjuvant chemotherapy and cytoreductive surgery on progression-free survival and overall survival in ovarian cancer cases.
Method
The retrospective study was conducted at the Department of Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital & Research Centre, Lahore, Pakistan, and comprised data from January 2019 to January 2022 of women diagnosed with stage III high-grade serous ovarian cancer who received neoadjuvant chemotherapy and underwent subsequent interval debulking surgery. The patients were divided into groups A and B based on time to surgery within 6 weeks and time to surgery more than 6 weeks, respectively. The endpoint was taken as progression-free survival and overall survival on follow-up. Data was analysed using SPSS 27.
Results
Of the 2,100 patients who underwent surgery for ovarian cancer, 118(5.6%) women with mean age 52.18±9.3 years (range: 28-73 years) were included; 53(45%) in group A and 65(55%) in group B. Overall recurrence rate in this cohort was 76(64.4%); 36 (67.9%) in group A and 40 (61.5%) in group B. The mean progression free-survival was 15±1.5 months in group A and 18±2 months in group B (p=0.854). The mean overall survival across the sample was 44±1.8 months, and intergroup difference was not significant. (p=0.336).
Conclusion
Delay in interval debulking surgery after neoadjuvant chemotherapy was not found to have a significant impact on progression-free survival and overall survival in ovarian cancer cases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gynaecologic Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan.
- Department of Gynaecology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan.
- Department of Surgery, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan.
- Department of Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan.
Zitieren
APA
Khalil, K. A., Habib, M., Usmani, A. S., Shah, M. A., Anwer, A. W., & Syed, A. A. (2025). Impact of delay in interval debulking surgery after neoadjuvant chemotherapy on survival in ovarian cancer. Journal of the Pakistan Medical Association. https://doi.org/10.47391/jpma.20168
Vancouver
Khalil KA, Habib M, Usmani AS, Shah MA, Anwer AW, Syed AA. Impact of delay in interval debulking surgery after neoadjuvant chemotherapy on survival in ovarian cancer. Journal of the Pakistan Medical Association. 2025. doi:10.47391/jpma.20168
BibTeX
@article{Khalil2025,
author = {Khalil, Kheyal Azam and Habib, Maria and Usmani, Afshan Saeed and Shah, Muhammad Ansab and Anwer, Abdul Wahid and Syed, Aamir Ali},
title = {Impact of delay in interval debulking surgery after neoadjuvant chemotherapy on survival in ovarian cancer},
journal = {Journal of the Pakistan Medical Association},
year = {2025},
doi = {10.47391/jpma.20168}
}
EUVIMED